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Breast cancer is a heterogeneous disease that necessitates proper patient classification to direct surgery,
pharmacotherapy, and radiotherapy. Despite patients within the same subgroup receiving similar pharmacotherapy,
substantial variation in clinical outcomes is observed. Pharmacogenetic variations with direct effect on
pharmacokinetics and pharmacodynamics play a central role in clinical outcomes. Pharmacogenetic markers
associated with clinical outcome are known as biomarkers. They are termed prognostic biomarkers when their
presence is associated with a specific clinical outcome. If the presence of such biomarkers guides treatment,
they are termed predictive biomarkers. A number of pharmacogenetic markers have been described in relation to
breast cancer pharmacotherapy both in the adjuvant and neoadjuvant setting. CYP2D6 allelic variants produce variable
rates of tamoxifen metabolism and are associated with survival outcomes. Other biomarkers have been described in
relation to other forms of endocrine therapy and trastuzumab. In neoadjuvant and adjuvant breast cancer
chemotherapy, specific biomarkers were correlated with clinical outcomes and risk of drug toxicity. This review
highlights key biomarkers in breast cancer pharmacotherapy with the potential of translating such study
outcomes into clinical practice.
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Breast cancer is the commonest female cancer diagnosed
in the USA and account for one in three female cancers
[1]. Such cancer patients are managed in multidisciplin-
ary teams that coordinate surgical treatment together
with administration of chemotherapy, hormonal therapy,
or immunotherapy. Classification of breast tumors plays
a critical role in this regard; primarily as different sub-
types are associated with a specific prognosis and clinical
outcome. Moreover, proper patient classification enables
optimization of treatment to a specific patient.
Breast histology and tumor grade and stage have been
classically used to classify breast tumors. With the advent
of improved laboratory techniques, molecular receptor
status of tumors has become empirical in breast cancer
classification. Routine diagnostic testing for receptors in
breast cancer includes the estrogen (ER), progesterone
(PR), and human epidermal growth factor receptor-2
(HER-2) [2]. The aforementioned receptors are markers of* Correspondence: godfrey.grech@um.edu.mt
Department of Pathology, University of Malta, Msida MSD2090, Malta
© 2015 Sacco and Grech. This is an Open Acc
License (http://creativecommons.org/licenses/
medium, provided the original work is proper
creativecommons.org/publicdomain/zero/1.0/prognostic outcome and guide pharmacologic treat-
ment. Being prognostic biomarkers, their presence or
absence is associated with clinical outcome irrespective
of treatment [3, 4].
Estrogen positive tumors can be treated with selective
estrogen receptor modulators (SERMs) such as tamoxi-
fen or aromatase inhibitors. HER-2 positive tumors on
the other hand show tumor regression in response to
the monoclonal antibody trastuzumab. However, subgroup
analysis of breast cancer patients showed substantial vari-
ation in clinical outcomes despite patients being on the
same pharmacotherapy. This led to the hypothesis that
there may be pharmacogenetic variations in patients
underlying different clinical outcomes. Pharmacogenetic
variations associated with pharmacokinetics and pharma-
codynamics of chemotherapy, hormonal and immunother-
apy, have been described. Predictive biomarkers comprise
measurable traits that identify patients that are likely to
benefit from treatment or exhibit adverse effects thereby
facilitating a predictive response to treatment [5]. This
review highlights the role of key pharmacogeneticess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Clinical effects observed with various pharmacogenetic
markers in patients on tamoxifen pharmacotherapy
Biomarker Effect Reference
CYP2D6 poor
metabolizers
Shorter relapse-free survival [11]
Higher recurrence rate [12]
Require increased tamoxifen dose [13]
UGT2B15 Increased risk of recurrence [17]
SULT1A1 Increased mortality risk [17]
Increased risk of recurrence [17]
ABCB1 Shorter relapse-free survival [20]
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endocrine, hormonal, and chemotherapy.
Pharmacogenetic markers of tamoxifen therapy
A significant proportion of breast tumors are positive for
the ER receptor. This makes the ER receptor a prognostic
biomarker, since its presence is associated with a favorable
prognosis. Further, as a predictive biomarker, it is an indi-
cation for prescribing hormonal therapy that interferes
with estrogen signaling. Pharmacological agents disrupt
estrogen signaling at various target sites hence blocking
tumor cell proliferation. Drugs affecting the estrogen
signaling pathway include SERMs such as tamoxifen and
raloxifene. Aromatase inhibitors (AIs) are the other major
class in this category with third-generation AIs including
exemestane, letrozole, and anastrozole. All of these drugs
have specific pharmacokinetic properties and thus vary in
their distribution, metabolism, and excretion pathways,
depending on activity of metabolizers and efficiency of
transporter proteins that are susceptible to genetic vari-
ation. Therefore, genetic variations affecting drug pharma-
cokinetics serve as valuable predictive biomarkers to select
patients for maximizing therapeutic effect and minimizing
side-effects [6].
Tamoxifen is the most widely prescribed SERM both in
locally advanced and metastatic ER positive breast cancer
patients [7]. Tamoxifen is a weak anti-estrogen metabolized
via CYP2D6 in the liver to produce endoxifen; a metabolite
of greater potency. CYP2D6 is a polymorphic gene with
more than 100 reported allelic variants, often due to single
nucleotide polymorphisms (SNPs) [8]. A number of
CYP2D6 alleles have been associated with either in-
creased or decreased enzyme activity. While CYP2D6*1
is the wild-type allele (resulting in normal enzyme
activity), *3, *4, and *5 are associated with negligible
enzyme activity, and *9, *10, and *17 result in decreased
enzyme activity. Depending on their CYP2D6 allelic
variants, patients have been classified as extensive (EM),
intermediate (IM), or poor metabolizers (PMs) [9–11].
These genomic variations were correlated with clinical
recurrence in retrospective studies. In a cohort of 225
breast cancer patients receiving adjuvant tamoxifen,
PMs had a shorter 2-year relapse free survival and a sig-
nificantly shorter time-to-recurrence as compared to
EM patients [11]. A subsequent retrospective study
demonstrated higher recurrence rates in PMs and IMs
of CYP2D6 [12]. This data suggest that selecting alterna-
tive drugs or tamoxifen dose adjustment would be indi-
cated for PMs. However, as no prospective trial has yet
shown adjuvant trial data, CYP2D6 genetic testing is not
routinely incorporated into clinical practice. Doubling
the dose of tamoxifen to 40 mg daily in Caucasian PMs
and IMs of CYP2D6 showed a significant increase in
endoxifen concentrations [13]. In patients of Japaneseorigin, a significantly higher concentration of plasma
endoxifen was identified in CYP2D6 *1/*10 and *10/*10
homozygotes, receiving 30 and 40 mg daily of tamoxifen,
respectively, with plasma endoxifen levels being compar-
able to wild-type individuals on standard dosing regi-
mens [14].
CYP2D6 variants are more prominent across ethnic
groups with non-Caucasians having a higher prevalence
of decreased CYP2D6 activity [15]. Such data show how
imperative it is to assess the risk-benefit ratio for each
individual patient, and such ethnic differences must be
considered when evaluating translational studies of gen-
omic research from bench to bedside. Due to ethnic dif-
ference, a meta-analysis found insufficient evidence to
robustly recommend CYP2D6 genotyping as a guide to
tamoxifen treatment [16].
Genetic variants of enzymes involved in tamoxifen inacti-
vation have been described. UDP-glucuronosyltransferase
(UGT) and sulfotransferase 1A1 (SULT1A1) convert active
tamoxifen to inactive soluble metabolites. Variations in
SULT1A1 and UGT2B15 alleles are associated with an in-
creased mortality risk in patients on tamoxifen [17]. How-
ever, there have been conflicting results with other studies
reporting no significant association between such variables
in efficacy [18, 19]. Other pharmacogenomic targets as-
sociated with tamoxifen metabolism have been studied
(Table 1). Interestingly, ABCB1 gene variants are asso-
ciated with multidrug resistance and decreased time-to-
recurrence [20]. However, results have been conflicting
among studies possibly owing to the differences in varia-
tions and genotype frequencies among different ethnic
cohorts.
Pharmacogenetic markers of aromatase inhibitors
While tamoxifen is converted to more active metabo-
lites, third generation AIs are inactivated by metabolic
pathways as the drugs letrozole, anastrozole, and exe-
mestane are already in their active form. The aromatase
enzyme catalyzes the conversion of androgens to estro-
gens and is coded by the CYP19A1 gene. The aromatase
enzyme is ubiquitous in fat tissue and is responsible for
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Given that the majority of breast cancer patients are
estrogen-receptor positive and postmenopausal, aromatase
is a significant therapy target in anti-tumor pharmacother-
apy. AIs as adjuvant hormonal therapy showed significant
improvement in disease-free survival and reduction in
breast cancer events when compared to tamoxifen in the
postmenopausal cohort [21]. However, side-effects mainly
of a musculoskeletal nature are rather prevalent. The fre-
quency and severity of such side-effects may be associated
with pharmacogenetic variation and may predict improved
treatment efficacy [22, 23].
As with CYP2D6 in tamoxifen metabolism, the
CYP19A1 gene is the mostly studied pharmacogenomic
target associated with AI efficacy and toxicity. Similar to
CYP2D6 a number of gene polymorphisms have been de-
scribed with substantial variation among ethnic groups
[24]. The effect of genetic polymorphisms of CYP19A1 on
response to AIs has produced conflicting results in studies.
A cohort of patients with stage 4 disease treated with
letrozole showed improved progression-free survival with
a variant in an untranslated region of CYP19 [25]. How-
ever, these results were not confirmed when this variable
was evaluated with other prognostic markers through
multivariate analysis [26]. SNPs were found to predict im-
proved efficacy of letrozole in neoadjuvant and adjuvant
treatment of postmenopausal patients [27]. Conversely,
SNPs such as a polymorphism in the 3′-UTR region of
CYP19 predicted a poor response to letrozole [28].
Genome-wide association studies (GWAS) comparing
toxicity of anastrozole to exemestane identified four SNPs
within the TCL1A gene associated with musculoskeletal
adverse events in women treated with AIs [29].
Identifying pharmacogenetic markers of trastuzumab
therapy
Trastuzumab is a humanized monoclonal antibody that
binds specifically to the HER-2 receptor that is overex-
pressed in HER-2-enriched tumors thereby inhibiting
cellular proliferation. HER-2 positive tumors are associ-
ated with a worse survival outcome compared to hor-
mone receptor positive tumors; thus, the HER-2
receptor qualifies as a prognostic biomarker [30]. As a
predictive biomarker, HER-2 positive patients qualify for
trastuzumab treatment, which reduces tumor recurrence
and overall mortality in combination with adjuvant
chemotherapy [31–33]. Varying response to trastuzumab
is observed, and tumor progression occurs in most
metastatic patients. Trastuzumab induces tumor cell
death through antibody dependent cell-mediated cyto-
toxicity (ADCC); a type II hypersensitivity reaction [34].
In metastatic HER-2 patients, the Fc gamma RIIIa-158
V/V genotype was associated with a higher rate of
trastuzumab-mediated adverse events, yet a paradoxicalimproved progression-free survival was observed [35, 36].
However, to date, other studies failed to replicate results.
The HER-2 receptor polymorphism I655V is associated
with increased protein tyrosine kinase activity [37]. Its
presence is associated with an aggressive phenotype and
higher tumorigenicity. In addition, the I655V is associated
with a higher risk of trastuzumab-induced cardiotoxicity
albeit no effect on patient survival was observed [38]. To
date, no suitable pharmacogenetic marker has been vali-
dated to optimize the benefit-risk ratio of patients under
trastuzumab therapy [39].
Pharmacogenomics altering outcomes of breast cancer
chemotherapy
Cytotoxic systemic chemotherapy is administered in the
neoadjuvant or adjuvant setting. As part of neoadjuvant
treatment, the primary aim of chemotherapy is to down-
stage tumors rendering them operable. The adjuvant set-
ting implies that chemotherapy is administered to a
patient in remission with no clinical or radiological evi-
dence of residual tumor. Adjuvant chemotherapy aims
to improve disease-free survival and overall survival
while minimizing the risk of recurrence [40]. The disad-
vantage of chemotherapy is the narrow therapeutic index
associated with such drugs and the subsequent systemic
toxicities that make them unpopular among patients.
Pharmacogenetics may explain the different patient out-
comes with respect to drug efficacy and toxicity [6, 41].
Genetic variants have been described associated with
altered pharmacokinetics of anthracyclines, taxanes, cyclo-
phosphamide, and capecitabine.
Doxorubicin is an anthracycline which inhibits the en-
zyme DNA topoisomerase II. It is commonly coadminis-
tered with cyclophosphamide and 5-fluorouracil and is
associated with significant risk of cardiotoxicity. Carbonyl
reductases are enzymes involved in the complex metabol-
ism of doxorubicin. The presence of the variant carbonyl
reductase 3 (CBR3) appeared as a double-edged sword in
a study of Asian breast cancer patients. While CBR3 was
associated with greater tumor reduction, patients expe-
rienced worse neutropenia [42]. In patients receiving
epirubicin, another anthracycline, the presence of a
polymorphism involved in drug conjugation (glucuronosyl-
transferase UGT2B7-His268T polymorphism) was asso-
ciated with increased recurrence of breast cancer [43].
Polymorphisms of enzymes involved with oxidative
stress have been associated with variable anthracycline-
induced clinical outcomes. Superoxide dismutase (SOD2)
and nitric oxide synthase (NOS3) variants have been asso-
ciated with decreased disease-free survival and decreased
progression-free survival, respectively [44, 45].
Capecitabine is a convenient form of chemotherapy as
it can be administered in the oral form. The drug is used
in stage IV disease and is the prodrug of 3-fluorouracil
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(DPD) catalyzes the rate-limiting step in the capecitabine
and 5FU degradation. Patients with homozygous gene
mutations for this enzyme suffer significant drug adverse
reactions secondary to drug accumulation [46]. Further,
splice variants of the DPD gene are associated with drug
toxicity [47]. Increased drug toxicity to capecitabine was
also observed in gene variants of the enzymes thymidy-
late synthase (TS) and methylenetetrahydrofolate reduc-
tase (MTHFR) [48].
Cyclophosphamide is a prodrug that is converted to
the active metabolite aldophosphamide in the liver. This
is then detoxified by aldehyde dehydrogenase 1A1
(ALDH1A1). This drug is ubiquitously prescribed in ad-
juvant breast cancer chemotherapy, yet there have been
significant variations in serum drug levels reported al-
though associations with clinical outcomes have been
conflicting. The presence of ALDH1A1 is associated
with triple-negative breast cancer which is known to
confer a poor prognosis, while patients receiving neoad-
juvant cyclophosphamide had worse clinical outcomes if
ALDH1A1 is expressed [49, 50].
Paclitaxel inhibits microtubule disaggregation thus dis-
rupting spindle formation and preventing cell division.
Paclitaxel is metabolized in the liver by CYP2C8 [51].
The variant allele CYP2C8 *3 was associated with a
higher rate of clinical remission with neoadjuvant pacli-
taxel treatment. However, increased rates of severe per-
ipheral neurotoxicity were documented [52]. Increased
risk of paclitaxel-associated peripheral neuropathy was
also noted in patients with the FANCD2 haplotype [53].
Conclusions
In the clinical setting, breast cancer patient treatment is
commonly stratified according to tumor stage, histology,
and presence or absence of the estrogen, progesterone,
and HER-2 receptors, enabling targeting therapy with
the aims of improving clinical outcomes while minimiz-
ing adverse events. In addition, molecular tumor profil-
ing classifies the patients into luminal A, luminal B, and
Basal subtypes. Of interest, patients within the same
subgroup undergoing similar treatment show variable
clinical outcomes. Genetic polymorphisms resulting in
altered proteins, functionally affecting drug pharmaco-
kinetics, have been shown to correlate with variable clin-
ical outcomes both with respect to survival and drug
toxicity. However, as yet, incorporation of pharmacoge-
nomic data to the clinical setting has been hindered by
a number of limitations. Primarily, results of pharmaco-
genomic studies have showed variable results. Thus,
reaching consensus on associated outcomes with phar-
macogenetic markers has been difficult. This may be
due to cohort variations secondary to different ethnic
groups or improper tumor classification. Further, somepharmacogenetic markers were associated with para-
doxical outcomes; showing improved clinical efficacy
and yet being associated with adverse drug toxicities.
Future approaches using genome-wide associations
may help identify other candidate genes as predictive
biomarkers. However, to replicate results, standard pa-
tient classification should be based on well-defined
breast cancer classification criteria while adopting
standard clinical guidelines [54]. This would enable
unmasking of confounding factors and hopefully facili-
tate the transition of using pharmacogenetic markers
for targeted therapy in breast cancer. An integrative
approach incorporating preventive and predictive bio-
markers, risk factors and clinical data, would be the
way forward to assisting targeting therapy providing a
personalised medicine treatment (PPPM) [55, 56].
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